These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17465253)

  • 1. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma.
    Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T
    Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical effects of tumor-associated macrophages and dendritic cells on renal cell carcinoma.
    Hamada I; Kato M; Yamasaki T; Iwabuchi K; Watanabe T; Yamada T; Itoyama S; Ito H; Okada K
    Anticancer Res; 2002; 22(6C):4281-4. PubMed ID: 12553070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
    Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
    Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
    Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
    Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack.
    Donskov F; von der Maase H; Marcussen N; Hamilton-Dutoit S; Madsen HH; Jensen JJ; Hokland M
    Clin Cancer Res; 2004 Dec; 10(23):7911-6. PubMed ID: 15585624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans.
    Rubin JT; Elwood LJ; Rosenberg SA; Lotze MT
    Cancer Res; 1989 Dec; 49(24 Pt 1):7086-92. PubMed ID: 2582450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
    Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma.
    Naglieri E; Gebbia V; Durini E; Lelli G; Abbate I; Selvaggi FP; Di Tonno P; Colucci G
    Anticancer Res; 1998; 18(3B):2021-6. PubMed ID: 9677460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma.
    Sievers E; Albers P; Schmidt-Wolf IG; Märten A
    J Urol; 2004 Jan; 171(1):114-9. PubMed ID: 14665857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
    Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidome from renal cell carcinoma contains antigens recognized by CD4+ T cells and shared among tumors of different histology.
    Tassi E; Facchinetti V; Seresini S; Borri A; Dell'antonio G; Garavaglia C; Casorati G; Protti MP
    Clin Cancer Res; 2006 Aug; 12(16):4949-57. PubMed ID: 16914584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between interleukin-12-expressing cells and antigen-presenting cells in patients with colorectal cancer.
    Inoue Y; Nakayama Y; Minagawa N; Katsuki T; Nagashima N; Matsumoto K; Shibao K; Tsurudome Y; Hirata K; Nagata N; Itoh H
    Anticancer Res; 2005; 25(5):3541-6. PubMed ID: 16101177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma.
    Minárik I; Lašťovička J; Budinský V; Kayserová J; Spíšek R; Jarolím L; Fialová A; Babjuk M; Bartůňková J
    Immunol Lett; 2013 May; 152(2):144-50. PubMed ID: 23721909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M; Mandic M; Wesa AK; Cavalcanti E; Dambrosio M; Mancini V; Battaglia M; Gesualdo L; Storkus WJ; Ranieri E
    J Immunother; 2008 Apr; 31(3):254-62. PubMed ID: 18317362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for metastatic renal cell carcinoma.
    McDermott DF; Rini BI
    BJU Int; 2007 May; 99(5 Pt B):1282-8. PubMed ID: 17441925
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo description of dendritic cells in human renal cell carcinoma.
    Schwaab T; Schned AR; Heaney JA; Cole BF; Atzpodien J; Wittke F; Ernstoff MS
    J Urol; 1999 Aug; 162(2):567-73. PubMed ID: 10411089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-viral delivery of interleukin-2 and soluble Flk-1 inhibits metastatic and primary tumor growth in renal cell carcinoma.
    Yockman JW; Kim WJ; Chang CW; Kim SW
    Gene Ther; 2007 Oct; 14(19):1399-405. PubMed ID: 17653245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.